NEUROPATHIC PAIN: CHALLENGES AND SOLUTIONS IN CLINICAL PRACTICE
Abstract
Neuropathic pain is caused by abnormal processing of signals in the peripheral and central nervous systems. It is characterized by pain occurring without external stimulation or long after the injury has passed. Typically, it is chronic, with patients describing it as burning, stinging, stabbing, or tingling. Causes include diabetes, herpes zoster, surgery, stroke, multiple sclerosis, tumors, and injuries. Despite significant advances in neuropathic pain research in recent years, therapeutic options remain limited and often insufficiently effective. Symptomatic therapy for neuropathic pain is based on the use of drugs from four basic groups: antidepressants, anticonvulsants, local analgesics, and opioids. In addition to pharmacological methods, non-pharmacological interventions are also used in the treatment of neuropathic pain. A combination of these methods with pharmacological therapy often yields the best results.
References
Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DL, Bouhassira D, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016;157(8):1599-606. doi: 10.1097/j.pain.0000000000000492.
Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380-7. doi: 10.1016/j.pain.2007.08.013.
Rahman W, Dickenson AH. Osteoarthritis-dependent changes in antinociceptive action of Nav1.7 and Nav1.8 sodium channel blockers: An in vivo electrophysiological study in the rat. Neuroscience. 2015;4;295:103-16. doi: 10.1016/j.neuroscience.2015.03.042.
Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9 (8):807-19. doi: 10.1016/S1474-4422(10)70143-5.
Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008; 29;70(18):1630-5. doi: 10.1212/01.wnl.0000282763.29778.59.
Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol. 2014;13(9):924-35. doi: 10.1016/S1474-4422(14)70102-4.
Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017; 16;3:17002. doi: 10.1038/nrdp.2017.2.
Dib-Hajj SD, Geha P, Waxman SG. Sodium channels in pain disorders: pathophysiology and prospects for treatment. Pain. 2017;158(Suppl 1):S97-S107. doi: 10.1097/j.pain.0000000000000854.
Ji RR, Donnelly CR, Nedergaard M. Astrocytes in chronic pain and itch. Nat Rev Neurosci. 2019;20(11):667-85. doi: 10.1038/s41583-019-0218-1.
Inoue K, Tsuda M. Microglia and neuropathic pain. Glia. 2018; 57(14):1469-79. doi: 10.1002/glia.20871.
Mitrović V, Marić S, Račić M, Petrović N. Neuropatski bol. U: Kulić M, Račić M (urednici): Bol, Univerzitet u Istočnom Sarajevu, Medicinski fakultet Foča, 2015; 57-69. [In Serbian].
Mitrović V, Marić S, Ćurčić B, Jovanović D, Loga-Andrijić N. Koncept neuropatskog bola: poreklo, mehanizam nastranka i terapijski pristup. U: Marić S, Mitrović V, Mladenović I (urednici): Savremeni pristup liječenju bola: monografija. Foča : Medicinski fakultet, 2023: 172-88. [In Serbian]
Xie HT, Xia ZY, Pan X, Zhao B, Liu ZG. Puerarin ameliorates allodynia and hyperalgesia in rats with peripheral nerve injury. Neural Regen Res. 2018; 13(7): 1263–8. doi: 10.4103/1673-5374.235074.
Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011; 152( Suppl 3): S2–S15. doi: 10.1016/j.pain.2010.09.030.
Haanpää M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152(1):14-27. doi: 10.1016/j.pain.2010.07.031.
Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain. 2011;152(12):2836-43. doi: 10.1016/j.pain.2011.09.014.
van Hecke O, Kamerman PR, Attal N, Baron R, Bjornsdottir G, Bennett DLH et al. Neuropathic pain phenotyping by international consensus (NeuroPPIC) for genetic studies: a NeuPSIG systematic review, Delphi survey, and expert panel recommendations. Pain. 2015;156(11):2337-53. doi: 10.1097/j.pain.0000000000000335.
Terkelsen AJ, Karlsson P, Lauria G, Freeman R, Finnerup NB, Jensen TS. The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes. Lancet Neurol. 2017;16(11):934-44. doi: 10.1016/S1474-4422(17)30329-0.
Lefaucheur JP, Wahab A, Planté-Bordeneuve V, Sène D, Ménard-Lefaucheur I, Rouie D, et al. Diagnosis of small fiber neuropathy: A comparative study of five neurophysiological tests. Neurophysiol Clin. 2015;45(6):445-55. doi: 10.1016/j.neucli.2015.09.012.
Roszkowska AM, Wylęgała A, Gargiulo L, Inferrera L, Russo M, Mencucci R, et al. Corneal Sub-Basal nerve plexus in non-diabetic small fiber polyneuropathies and the diagnostic role of in vivo corneal confocal microscopy. J Clin Med. 2023;13;12(2):664. doi: 10.3390/jcm12020664.
Jiang MS, Yuan Y, Gu ZX, Zhuang SL. Corneal confocal microscopy for assessment of diabetic peripheral neuropathy: a meta-analysis. Br J Ophthalmol. 2016;100 (1):9-14. doi: 10.1136/bjophthalmol-2014-306038.
Krämer HH, Schmelz M, Birklein F, Bickel A. Electrically stimulated axon reflexes are diminished in diabetic small fiber neuropathies. Diabetes. 2004;53(3):769-74. doi: 10.2337/diabetes.53.3.769.
Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015; 2015(7):CD008242. doi: 10.1002/14651858.CD008242.
Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88. doi: 10.1111/j.1468-1331.2010.02999.x.
Waldfogel JM, Nesbit SA, Dy SM, Sharma R, Zhang A, Wilson LM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review. Neurology. 2017;88(20):1958-67. doi: 10.1212/WNL.0000000000003882.
Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J. Amitriptyline versus placebo in postherpetic neuralgia. Neurology. 1982;32(6):671-3. doi: 10.1212/wnl.32.6.671.
Leijon G, Boivie J. Central post-stroke pain: a controlled trial of amitriptyline and carbamazepine. Pain. 1989;36(1):27-36. doi: 10.1016/0304-3959(89)90108-5.
Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;2014(1):CD007115. doi: 10.1002/14651858.CD007115.pub3.
Mitrović V, Baščarević V, Stolić R, Mitrović V, Filipović-Danić S. Intracystic hemorrhage in the lumbar spine as a cause of sudden leg weakness-a case report. Sanamed. 2024; 19(2): 211-4. doi: 10.5937/sanamed0-51878.
Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;2015(8):Cd011091. doi: 10.1002/14651858.CD011091.pub2.
Aiyer R, Barkin RL, Bhatia A. Treatment of neuropathic pain with Venlafaxine: a systematic review. Pain Med. 2017; 1;18(10):1999-2012. doi: 10.1093/pm/pnw261.
Binder A, Baron R. The pharmacological therapy of chronic neuropathic pain. Dtsch Arztebl Int. 2016; 16;113(37):616-25. doi: 10.3238/arztebl.2016.0616.
Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):CD007938. doi: 10.1002/14651858.CD007938.pub4.
Hong LM, Liu JM, Lin L, Huang CC, Chen R, Lin WW. Modeling an evaluation of the efficacy of the novel neuroanalgesic drug mirogabalin for diabetic peripheral neuropathic pain and postherpetic neuralgia therapy. Eur J Pharm Sci. 2024;1;197:106777. doi: 10.1016/j.ejps.2024.106777.
Thomas AM, Atkinson TJ. Old friends with new faces: are sodium channel blockers the future of adjunct pain medication management? J Pain. 2018;19(1):1-9. doi: 10.1016/j.jpain.2017.08.001.
Navez ML, Monella C, Bosl I, Sommer D, Delorme C. 5% Lidocaine medicated plaster for the treatment of postherpetic neuralgia: a review of the clinical safety and tolerability. Pain Ther. 2015;4(1):1-15. doi: 10.1007/s40122-015-0034-x.
van Nooten F, Treur M, Pantiri K, Stoker M, Charokopou M. Capsaicin 8% Patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther. 2017;39(4):787-803.e18. doi: 10.1016/j.clinthera.2017.02.010.
Lakhan SE, Velasco DN, Tepper D. Botulinum toxin-A for painful diabetic neuropathy: a meta-analysis. Pain Med. 2015;16(9):1773-80. doi: 10.1111/pme.12728.
Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain 2013;29(10):857–64. doi: 10.1097/AJP.0b013e31827a72d2.
Wu CJ, Lian YJ, Zheng YK, Zhang HF, Chen Y, Xie NC, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, doubleblind, placebo-controlled trial. Cephalalgia 2012;32(6):443–50. doi: 10.1177/0333102412441721.
Safarpour Y, Jabbari B. Botulinum toxin treatment of pain syndromes -an evidence based review. Toxicon. 2018:147:120-8. doi: 10.1016/j.toxicon.2018.01.017.
Duehmke RM, Derry S, Wiffen PJ, Bell RF, Aldington D, Moore RA. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):CD003726. doi: 10.1002/14651858.CD003726.pub4.
Gaskell H, Derry S, Stannard C, Moore RA. Oxycodone for neuropathic pain in adults. Cochrane Database Syst Rev. 2016;7(7):CD010692. doi: 10.1002/14651858.CD010692.pub3.
Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag 2014, 19(6):328-35. doi: 10.1155/2014/754693.
Häuser W, Finn DP, Kalso E, Krcevski-Skvarc N, Kress HG, Morlion B, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22(9):1547-64. doi: 10.1002/ejp.1297.
Meng H, Johnston B, Englesakis M, Moulin DE, Bhatia A. Selective cannabinoids for chronic neuropathic pain: a systematic review and meta-analysis. Anesth Analg. 2017;125(5):1638-52. doi: 10.1213/ANE.0000000000002110.
Chen SH, Lin YW, Tseng WL, Lin WT, Lin SC, Hsueh YY. Ultrahigh frequency transcutaneous electrical nerve stimulation for neuropathic pain alleviation and neuromodulation. Neurotherapeutics. 2024;21(3):e00336. doi: 10.1016/j.neurot.2024.e00336.
Copyright (c) 2025 Sanamed
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal Sanamed is published under an Open Access license. All its content is available free of charge. Users can read, download, copy, distribute, print, search the full text of articles, as well as establish HTML links to them, without having to seek the consent of the author or publisher.
The right to use content without consent does not release the users from the obligation to give the credit to the journal and its content in a manner described under CC BY.